LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Landsteiner Lung Cancer Research Platform (LALUCA) A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
500 participants
Apr 17, 2020
OBSERVATIONAL
Conditions
Summary
This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.
Eligibility
Inclusion Criteria4
- Informed consent
- Histologically confirmed lung cancer
- Age ≥ 18 years
- Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
Exclusion Criteria1
- \-
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04733430